Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998-2010.

Abstract:

OBJECTIVES:Adipose tissue affects several aspects of the cellular immune system, but prior epidemiological studies have differed on whether a higher body mass index (BMI) promotes CD4 T-cell recovery on antiretroviral therapy (ART). The objective of this analysis was to assess the relationship between BMI at ART initiation and early changes in CD4 T-cell count. METHODS:We used the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) data set to analyse the relationship between pre-treatment BMI and 12-month CD4 T-cell recovery among adults who started ART between 1998 and 2010 and maintained HIV-1 RNA levels < 400 copies/mL for at least 6 months. Multivariable regression models were adjusted for age, race, sex, baseline CD4 count and HIV RNA level, year of ART initiation, ART regimen and clinical site. RESULTS:A total of 8381 participants from 13 cohorts contributed data; 85% were male, 52% were nonwhite, 32% were overweight (BMI 25-29.9 kg/m(2) ) and 15% were obese (BMI > 30 kg/m(2) ). Pretreatment BMI was associated with 12-month CD4 T-cell change (P < 0.001), but the relationship was nonlinear (P < 0.001). Compared with a reference of 22 kg/m(2) , a BMI of 30 kg/m(2) was associated with a 36 cells/μL [95% confidence interval (CI) 14, 59 cells/μL] greater CD4 T-cell count recovery among women and a 19 cells/μL (95% CI 9, 30 cells/μL) greater recovery among men at 12 months. At a BMI > 30 kg/m(2) , the observed benefit was attenuated among men to a greater degree than among women, although this difference was not statistically significant. CONCLUSIONS:A BMI of approximately 30 kg/m(2) at ART initiation was associated with greater CD4 T-cell recovery at 12 months compared with higher or lower BMI values, suggesting that body composition may affect peripheral CD4 T-cell recovery.

journal_name

HIV Med

journal_title

HIV medicine

authors

Koethe JR,Jenkins CA,Lau B,Shepherd BE,Silverberg MJ,Brown TT,Blashill AJ,Anema A,Willig A,Stinnette S,Napravnik S,Gill J,Crane HM,Sterling TR,North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

doi

10.1111/hiv.12259

subject

Has Abstract

pub_date

2015-10-01 00:00:00

pages

572-7

issue

9

eissn

1464-2662

issn

1468-1293

journal_volume

16

pub_type

杂志文章
  • Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.

    abstract:OBJECTIVE:To compare virological and immunological responses to nevirapine (NVP)-based and efavirenz (EFV)-based highly active antiretroviral therapy (HAART) regimens in antiretroviral-naïve patients with advanced HIV infection. METHODS:A retrospective observational cohort study was conducted on antiretroviral-naïve H...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2004.00195.x

    authors: Manosuthi W,Sungkanuparph S,Vibhagool A,Rattanasiri S,Thakkinstian A

    更新日期:2004-03-01 00:00:00

  • Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.

    abstract:OBJECTIVES:Although current guidelines recommend resistance testing prior to antiretroviral therapy (ART) reinitiation after treatment interruptions, virological failure of first-line ritonavir-boosted, protease-inhibitor (PI/r)-containing ART is associated with low emergent PI resistance. In patients experiencing unsc...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12107

    authors: Tinago W,O'Halloran JA,O'Halloran RM,Macken A,Lambert JS,Sheehan GJ,Mallon PW

    更新日期:2014-04-01 00:00:00

  • Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis.

    abstract:OBJECTIVES:Anaemia represents a common toxicity with amphotericin B-based induction therapy in HIV-infected persons with cryptococcal meningitis. We sought to examine the impact of amphotericin-related anaemia on survival. METHODS:We used data from Ugandan and South African trial participants to characterize the varia...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12387

    authors: Tugume L,Morawski BM,Abassi M,Bahr NC,Kiggundu R,Nabeta HW,Hullsiek KH,Taseera K,Musubire AK,Schutz C,Muzoora C,Williams DA,Rolfes MA,Meintjes G,Rhein J,Meya DB,Boulware DR

    更新日期:2017-01-01 00:00:00

  • An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile.

    abstract:OBJECTIVES:Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, is a drug that is frequently included in highly active antiretroviral therapy for treatment of HIV infection. Decreased bioavailability and increased toxicity limit its use. We report a formulation of efavirenz-loaded lactoferrin nanoparticle...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12475

    authors: Kumar P,Lakshmi YS,Kondapi AK

    更新日期:2017-08-01 00:00:00

  • Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France.

    abstract:OBJECTIVES:The aims of the present study were to estimate the prevalence of renal impairment (RI) among HIV-infected adult patients and to investigate the associated factors. METHODS:A cross-sectional survey was conducted in a French hospital-based cohort. Clearance of creatinine (CC) was calculated using the Cockcrof...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2009.00780.x

    authors: Déti EK,Thiébaut R,Bonnet F,Lawson-Ayayi S,Dupon M,Neau D,Pellegrin JL,Malvy D,Tchamgoué S,Dabis F,Morlat P,Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

    更新日期:2010-05-01 00:00:00

  • HIV/hepatitis C virus and HIV/hepatitis B virus coinfections protect against antiretroviral-related hyperlipidaemia.

    abstract:INTRODUCTION:Hyperlipidaemia is a recognized complication of HIV antiretroviral therapy. The interactions among HIV, viral hepatitis, antiretroviral therapies and lipids are poorly understood. METHODS:Ontario HIV Treatment Network Cohort Study participants with at least one lipid level after highly active antiretrovir...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2010.00897.x

    authors: Diong C,Raboud J,Li M,Cooper C,Ontario HIV Treatment Network Cohort Study Team.

    更新日期:2011-08-01 00:00:00

  • Low plasma levels of dehydroepiandrosterone sulphate in HIV-positive patients coinfected with hepatitis C virus.

    abstract:OBJECTIVES:To evaluate plasma levels of dehydroepiandrosterone sulphate (DHEAS) in a cohort of HIV-infected patients and to analyse factors associated with DHEAS levels. METHODS:We conducted a cross-sectional survey in the Nîmes University Hospital cohort of HIV-infected patients in south-eastern France. All HIV-infec...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2004.00203.x

    authors: Mauboussin JM,Mahamat A,Peyrière H,Rouanet I,Fabbro-Peray P,Daures JP,Vincent D

    更新日期:2004-05-01 00:00:00

  • Merkel cell carcinoma and multiple basal cell carcinoma in an African albino woman with HIV infection.

    abstract::A 25-year-old HIV-infected African albino woman developed an aggressive Merkel cell carcinoma on her face and at least 10 basal cell carcinomas, mainly on sun-exposed parts of her body. HIV infection, immune deficiency and sun exposure are known risk factors for the development of Merkel cell carcinoma. Chemotherapy a...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2004.00252.x

    authors: Colebunders R,Bottieau E,Van den Brande J,Colpaert C,Van Marck E

    更新日期:2004-11-01 00:00:00

  • Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection.

    abstract:OBJECTIVES:To study the impact of highly active antiretroviral therapy (HAART) on isotype switching and avidity maturation of HIV-1-specific immunoglobulin G (IgG) in patients with primary HIV-1 infection (PHI). METHODS:We studied the emergence and the evolution of anti-HIV IgG antibodies by quantitative immunoblottin...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2006.00406.x

    authors: Adalid-Peralta L,Grangeot-Keros L,Rudent A,Ngo-Giang-Huong N,Krzysiek R,Goujard C,Deveau C,Le Gall M,Meyer L,Emilie D,Rouzioux C

    更新日期:2006-11-01 00:00:00

  • Monitoring of older HIV-1-positive adults by HIV clinics in the United Kingdom: a national quality improvement initiative.

    abstract:OBJECTIVES:The aim of the study was to describe a UK-wide process to assess adherence to guidelines for the routine investigation and monitoring of HIV-positive adults aged ≥ 50 years and provide clinical services with individual feedback to support improvement in quality of care. METHODS:The British HIV Association (...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12842

    authors: Ekong N,Curtis H,Ong E,Sabin CA,Chadwick D,British HIV Association (BHIVA) Audit and Standards Sub-Committee.

    更新日期:2020-08-01 00:00:00

  • Kaposi's sarcoma in HIV-infected patients: treatment options.

    abstract::Kaposi's sarcoma (KS) is the most prevalent AIDS-associated tumour, occurring in 20-30% of HIV-1-infected individuals in the early 1980s. The introduction of highly active antiretroviral therapy (HAART) has dramatically reduced the incidence of the disease and might therefore support the concept of 'opportunistic mali...

    journal_title:HIV medicine

    pub_type: 杂志文章,评审

    doi:10.1046/j.1468-1293.2000.00027.x

    authors: Hermans P

    更新日期:2000-07-01 00:00:00

  • Prevention of cryptococcosis in HIV-infected patients with limited access to highly active antiretroviral therapy: evidence for primary azole prophylaxis.

    abstract::Despite advances in the treatment of HIV disease, the incidence and mortality of invasive cryptococcal disease remain significant. A matched, case-control study was performed to examine the impact of highly active antiretroviral therapy (HAART) and azole use on the incidence of invasive cryptococcal disease in HIV-inf...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2005.00289.x

    authors: Cantey PT,Stephens DS,Rimland D

    更新日期:2005-07-01 00:00:00

  • Effectiveness and safety of protease inhibitor-based regimens in HIV-infected Thai children failing first-line treatment.

    abstract:OBJECTIVES:Virological failure on first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based treatment regimens has become a problem in HIV-infected children on long-term antiretroviral therapy (ART). Protease inhibitor (PI)-based regimens are therefore often given to children failing NNRTI-based regimens. ...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2012.01061.x

    authors: Wattanutchariya N,Sirisanthana V,Oberdorfer P

    更新日期:2013-04-01 00:00:00

  • Potential lung cancer screening outcomes using different age and smoking thresholds in the ANRS-CO4 French Hospital Database on HIV cohort.

    abstract:OBJECTIVES:In most lung screening programmes, only subjects ≥ 55 years old and smoking ≥ 30 pack-years are eligible to undergo chest low-dose computed tomography. Whether the same criteria should apply to people living with HIV (PLHIV) is uncertain, given the increased lung cancer risks associated with immunodeficiency...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12811

    authors: Makinson A,Tron L,Grabar S,Milleron B,Reynes J,Le Moing V,Morquin D,Lert F,Costagliola D,Guiguet M

    更新日期:2020-03-01 00:00:00

  • Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.

    abstract:BACKGROUND:ODIN (once-daily darunavir in treatment-experienced patients) was a 48-week, phase III, randomized, open-label trial comparing once-daily (qd) darunavir/ritonavir (DRV/r) 800/100 mg with twice-daily (bid) DRV/r 600/100 mg, both with an optimized background regimen [OBR; at least two nucleoside reverse transc...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/hiv.12024

    authors: Sension M,Cahn P,Domingo P,Hodder S,Opsomer M,Lathouwers E,Van de Casteele T,Tomaka F

    更新日期:2013-08-01 00:00:00

  • There and back again: the impact of adult HIV prevalence on national life expectancies.

    abstract::Worldwide we have seen dramatic increases in HIV prevalence and decreases in life expectancy over the last decade. The aim of this study was to determine the association between HIV prevalence and life expectancy. A strong negative association between adult HIV prevalence and life expectancy was observed for 137 count...

    journal_title:HIV medicine

    pub_type: 信件

    doi:10.1111/j.1468-1293.2005.00266.x

    authors: McGuire AL,Barer JM,Montaner JS,Hogg RS

    更新日期:2005-03-01 00:00:00

  • Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.

    abstract:OBJECTIVES:Abacavir (ABC) selects for four mutations (K65R, L74V, Y115F and M184V) in HIV-1 reverse transcriptase (RT), both in vitro and during monotherapy in vivo. The aim of this analysis was to compare the selection of these and other nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations by ABC-con...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2004.00243.x

    authors: Lanier ER,Givens N,Stone C,Griffin P,Gibb D,Walker S,Tisdale M,Irlbeck D,Underwood M,St Clair M,Ait-Khaled M

    更新日期:2004-11-01 00:00:00

  • De-simplifying single-tablet antiretroviral treatments: uptake, risks and cost savings.

    abstract:OBJECTIVES:As more HIV-positive individuals receive antiretroviral therapy (ART), payers are seeking options for covering these increased and sustained drug costs. Strategic use of available generic antiretroviral (ARV) formulations may be feasible. De-simplifying a single-tablet co-formulation (STF) into two or more t...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12701

    authors: Krentz HB,Campbell S,Lahl M,Gill MJ

    更新日期:2019-03-01 00:00:00

  • Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).

    abstract:OBJECTIVES:Dyslipidaemic effects of antiretrovirals (ARVs) may contribute to increased cardiovascular risk (CR) in HIV-1-infected patients. The ARTEN (atazanavir/ritonavir on a background of tenofovir and emtricitabine vs. nevirapine on the same background, in naïve HIV-1-infected patients) study compared prospectively...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1468-1293.2011.00917.x

    authors: Podzamczer D,Andrade-Villanueva J,Clotet B,Taylor S,Rockstroh JK,Reiss P,Domingo P,Gellermann HJ,de Rossi L,Cairns V,Soriano V

    更新日期:2011-07-01 00:00:00

  • A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.

    abstract:OBJECTIVES:To compare the safety and efficacy of amprenavir [APV/j Agenerase trade mark; GlaxoSmithKline, [Ware, UK; 600 mg twice a day (bid)] boosted with low-dose ritonavir (RTV, 100 mg bid) with those of other protease inhibitors (PIs) in PI-experienced HIV-infected patients. STUDY DESIGN:Parallel-group, randomized...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1468-1293.2004.00224.x

    authors: Pulido F,Katlama C,Marquez M,Thomas R,Clumeck N,Pedro Rde J,Cattelan AM,Zhu C,Tymkewycz P

    更新日期:2004-07-01 00:00:00

  • Associations of marijuana with markers of chronic lung disease in people living with HIV.

    abstract:OBJECTIVES:The relationship between marijuana use and markers of chronic lung disease in people living with HIV (PLWH) is poorly understood. METHODS:We performed a cross-sectional analysis of the Examinations of HIV-Associated Lung Emphysema (EXHALE) study, including 162 HIV-positive patients and 138 participants with...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12966

    authors: Wenger DS,Triplette M,Shahrir S,Akgun KM,Wongtrakool C,Brown ST,Kim JW,Soo Hoo GW,Rodriguez-Barradas MC,Huang L,Feemster LC,Zifodya J,Crothers K

    更新日期:2021-02-01 00:00:00

  • Utilization of absolute monocyte counts to predict cardiovascular events in people living with HIV.

    abstract:OBJECTIVES:Cardiovascular risk is increased in people living with HIV (PLWH). In HIV-uninfected populations, total absolute monocyte count (AMC) has been shown to be predictive of future cardiovascular events (CVEs). We sought to determine whether AMC predicts CVEs in PLWH independent of established and HIV-related car...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.13018

    authors: Bogorodskaya M,Lyass A,Mahoney TF,Borowsky LH,Sen P,Swirski FK,Srinivasa S,Longenecker CT,Massaro JM,D'Agostino RB Sr,Triant VA

    更新日期:2020-12-08 00:00:00

  • Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.

    abstract:OBJECTIVE:To assess the incidence and consequences of adverse reactions among African HIV-positive pregnant women treated with fixed-dose combinations of a nevirapine-containing antiretroviral (ARV) triple therapy. METHODS:A retrospective analysis of the clinical files of 703 HIV-1-positive pregnant women treated with...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2006.00386.x

    authors: Marazzi MC,Germano P,Liotta G,Guidotti G,Loureiro S,da Cruz Gomes A,Valls Blazquez MC,Narciso P,Perno CF,Mancinelli S,Palombi L

    更新日期:2006-07-01 00:00:00

  • HIV prevalence and HIV clinical outcomes of transgender and gender-diverse people in England.

    abstract:OBJECTIVES:We provide the first estimate of HIV prevalence among trans and gender-diverse people living in England and compare outcomes of people living with HIV according to gender identity. METHODS:We analysed a comprehensive national HIV cohort and a nationally representative self-reported survey of people accessin...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12987

    authors: Kirwan PD,Hibbert M,Kall M,Nambiar K,Ross M,Croxford S,Nash S,Webb L,Wolton A,Delpech VC

    更新日期:2021-02-01 00:00:00

  • Late presentation of HIV infection: a consensus definition.

    abstract:OBJECTIVES:Across Europe, almost a third of individuals infected with HIV do not enter health care until late in the course of their infection. Surveillance to identify the extent to which late presentation occurs remains inadequate across Europe and is further complicated by the lack of a common clinical definition of...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2010.00857.x

    authors: Antinori A,Coenen T,Costagiola D,Dedes N,Ellefson M,Gatell J,Girardi E,Johnson M,Kirk O,Lundgren J,Mocroft A,D'Arminio Monforte A,Phillips A,Raben D,Rockstroh JK,Sabin C,Sönnerborg A,De Wolf F,European Late Presenter

    更新日期:2011-01-01 00:00:00

  • Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.

    abstract:BACKGROUND:Tuberculosis (TB) is a common opportunistic infection among HIV-infected people, and rifampicin is an important drug for the treatment of TB. However, administration of rifampicin in combination with antiretroviral therapy, particularly protease inhibitors, is difficult because of drug-drug interactions. ME...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2007.00442.x

    authors: Mallolas J,Sarasa M,Nomdedeu M,Soriano A,López-Púa Y,Blanco JL,Martínez E,Gatell JM

    更新日期:2007-03-01 00:00:00

  • Better preserved immune responses after immunization with rgp 160 in HIV-1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow-up.

    abstract:OBJECTIVE:To study the impact of effective highly active antiretroviral therapy (HAART) on the preservation of long-term CD4 memory cells induced by vaccines in HIV-1-infected patients. METHODS:Thirty HIV-1-positive patients on HAART with undetectable viral load were randomized into three groups: 10 received HIV-1 rgp...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1468-1293.2003.00148.x

    authors: Hejdeman B,Leandersson AC,Fredriksson EL,Sandström E,Wahren B,Bratt G

    更新日期:2003-04-01 00:00:00

  • Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice.

    abstract:OBJECTIVES:Effective HIV therapy reflects suppression of plasma HIV RNA levels below assay detection thresholds, although lower levels of "residual viraemia" have also been demonstrated over extended periods of effective antiretroviral treatment. Here we examine the determinants of HIV RNA suppression below the standar...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12323

    authors: McKinnon E,Castley A,Payne L,Pummer S,Nolan D

    更新日期:2016-08-01 00:00:00

  • Universal test and treat in relation to HIV disease progression: results from a stepped-wedge trial in Eswatini.

    abstract:OBJECTIVES:Universal test and treat (UTT) is recommended for people living with HIV (PLHIV) to reduce morbidity/mortality and minimize transmission. However, concerns exist that this strategy may lead to more crowded hospitals, longer wait times and poorer service, adversely impacting health outcomes for clients with s...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12941

    authors: Boeke CE,Khan S,Walsh F,Hettema A,Lejeune C,Spiegelman D,Okello V,Harwell J,Mazibuko S,Bärnighausen T

    更新日期:2021-01-01 00:00:00

  • Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.

    abstract:BACKGROUND:The addition of a low dose of ritonavir to protease inhibitors (PIs) has become a widespread strategy to improve PI pharmacokinetics. As resistance is a major barrier to long-term suppression, in salvage therapy genotype and/or phenotype scoring is currently used to predict the response. We evaluated the rel...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2007.00464.x

    authors: Mallolas J,Blanco J,Labarga P,Vergara A,Ocampo A,Sarasa M,Arnedo M,López-Púa Y,García J,Juega J,Guelar A,Terrón A,Dalmau D,García I,Zárraga M,Martínez E,Carné X,Pumarola T,Escayola R,Gatell J

    更新日期:2007-05-01 00:00:00